Congress mandates free prostate cancer screening for high-risk men

What it does

This bill requires health insurance plans to cover prostate cancer screenings without cost-sharing (copays, deductibles, coinsurance) for men age 40+ who are at high risk—specifically African-American men and men with a family history of prostate cancer. The bill is grounded in evidence that early detection dramatically improves survival rates and that African-American men face disproportionately higher incidence and mortality from prostate cancer.

Why we flagged it

The bill's operative mechanism is a straightforward mandate requiring health plans to cover a specific preventive screening without cost-sharing. It is a public-health measure addressing documented health disparities, not a tax provision, subsidy, or deregulation.

What the text implies

• Clause (3) freezes breast cancer screening recommendations to those issued before November 2009, potentially excluding newer evidence-based screening protocols—this appears to be a legislative lock-in that may limit future updates to women's preventive care standards.
• The definition of 'high-risk' in paragraph (2) is broad (first-degree relative with prostate cancer, cancer associated with increased risk, or genetic alteration associated with increased risk) and may expand coverage beyond the stated focus on African-American men and direct family history.
• Plans cannot deny coverage for non-recommended services (paragraph 4), but the bill does not address whether plans may impose cost-sharing on screenings beyond those mandated, creating potential for tiered coverage.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

High-risk men gain access to preventive screening without cost barriers, enabling earlier detection when survival rates are near 100% versus 37% for late-stage disease. The bill addresses documented health disparities affecting African-American men, who face 2.1× higher mortality and 70% higher incidence than White men.

Who stands to gain

• men age 40+ at high risk of prostate cancer (primary beneficiaries—gain free screening access)
• diagnostic and screening service providers (labs, imaging centers, urologists—increased volume of co

Named in the bill

Public Health Service Act, United States Preventive Services Task Force, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Health Resources and Services Administration, group health plans, health insurance issuers

Where it stands

38 cosponsors: 31 Democrats, 7 Republicans.

• Feb 13, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 13, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,779,655 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Neal Dunn, the sponsor, reported $438,583 in PAC receipts in the 2026 cycle.

• Astellas Pharma Us, Inc. — $1,490,000 on 2 filings
• Zero Prostate Cancer — $253,655 on 2 filings
• Dana-farber Cancer Institute — $36,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.